Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation

Leukemia and Lymphoma

Volumn 58, Issue 3, 2017, Pages 754-755

  Aslan, Alma ^a   Aras, Tülin ^b   Özdemir, Evren ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Pozitron Nuclear Diagnostics Center   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CHLORAMBUCIL; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; NIVOLUMAB; OXALIPLATIN; PREDNISONE; PREGABALIN; VINBLASTINE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER THERAPY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COUGHING; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HLA TYPING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEAKNESS; WEIGHT REDUCTION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; RECURRENT DISEASE; RETREATMENT;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RECURRENCE; RETREATMENT; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84981285559     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1213835     Document Type: Letter

References (7)

1. Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma:a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1:433–440.
2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
3. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–319.
4. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12:172–183.
5. Angenendt L, Schliemann Lutz M, et al. Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:443–445.
6. Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850–852.
7. Villasboas JC, Ansell SM, Witzig TE., Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget. 2016;7:13260–13264.